Company Description
TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers.
Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.
The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B.
In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells.
TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.
| Country | United States |
| Founded | 2016 |
| IPO Date | Jul 9, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Thomas A. Fitzgerald M.B.A. |
Contact Details
Address: 6 Liberty Square, #2382 Boston, Massachusetts 02109 United States | |
| Phone | 857-301-6857 |
| Website | transcodetherapeutics.com |
Stock Details
| Ticker Symbol | RNAZ |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001829635 |
| CUSIP Number | 89357L105 |
| ISIN Number | US89357L3033 |
| Employer ID | 81-1065054 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Thomas A. Fitzgerald M.B.A. | Interim Chief Executive Officer, Chief Financial Officer, President, Vice President of Administration and Director |
| Dr. Philippe P. Calais Ph.D., Pharm., Pharm.D. | Executive Chairman of the Board |
| Dr. Zdravka Medarova Ph.D. | Co-Founder and Chief Scientific Officer |
| Dr. Anna Moore Ph.D. | Co-Founder, Scientific Advisor and Member of Scientific Advisory Board |
| Susan Duggan M.B.A., R.N. | Senior Vice President of Operations |
| Dr. Daniel R. Vlock M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 5, 2024 | 8-K | Current Report |
| Apr 1, 2024 | 10-K | Annual Report |
| Feb 15, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 31, 2024 | 8-K | Current Report |
| Jan 22, 2024 | 8-K | Current Report |
| Jan 22, 2024 | 424B4 | Prospectus |
| Jan 18, 2024 | EFFECT | Notice of Effectiveness |
| Jan 18, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |